Researchers at the University of East Anglia (UEA) and the Norfolk and Norwich University Hospital (NNUH) in the UK have completed a clinical trial assessing a dizziness monitoring device.
The Continuous Ambulatory Vestibular Assessment (CAVA) device is designed as a wearable headset to diagnose the most common sources of dizziness.
According to the researchers, it is lightweight, durable and can be worn day and night. The device monitors head and eye movements in order to enable analysis of dizziness attacks outside hospitals.
When tested for detecting eye flicker (nystagmus), the device was found to be 99% accurate.
The study evaluated the accuracy, reliability and safety of CAVA in 17 subjects who did not have dizziness problems.
Participants wore the device for up to 30 days, allowing the capture of 9,000 hours of eye and head movement data, equivalent to 405 days.
According to study principal investigator John Phillips, the first phase of the trial involved artificially induced nystagmus in healthy patients.
In addition to 99% detection sensitivity, the device showed a specificity of 98.6% in detecting short periods of the induced eye flicker.
The results have been published in the Scientific Reports journal, where researchers noted that the CAVA device was reliable and operated an ambulatory monitor with a favourable tolerability profile.
Phillips said: “Following years of development, I’m delighted that this project was successful in identifying short periods of visually induced nystagmus with a high degree of accuracy.
“The success of this trial has proven the potential of this to fulfil a clinical need and establishing a new field of medicine: vestibular telemetry.”
Based on these findings, the researchers plan to perform another study to investigate the device’s diagnostic accuracy in patients with dizziness problems.